A product launch compresses months of decisions into days. Pricing questions, a server that falls over, an investor who wants a call now, a hire who chose this week to quit, and a marketing email with a typo that went to eleven thousand people. The problem for a founder is rarely intelligence. It is cognitive load: too many open loops, too little sleep, and the steady erosion of judgment that comes from both. Some founders reach for a smart drug at this point. This article looks at whether that helps, what it costs, and how to use a cognitive enhancer during a launch in a way you will not regret in the post-mortem.
What Cognitive Load Actually Is
Cognitive load is the amount of working memory a task demands. Working memory is small, roughly four to seven items in most people, and it is the bottleneck through which all deliberate thinking passes. A launch overwhelms it in three ways:
- Intrinsic load from genuinely hard problems, like a pricing decision with five interacting variables.
- Extraneous load from noise: notifications, unclear ownership, context switching between engineering, sales, and support.
- Open loops from tasks that are started but unresolved, which the mind keeps rehearsing in the background.
Sleep deprivation shrinks working memory further and, crucially, blunts your awareness that it has shrunk. This is the trap: the more overloaded you are, the less able you are to notice that your decisions are degrading.
A smart drug addresses one part of this picture directly and the others not at all. Understanding which part is the whole game.
What a Eugeroic Does for a Founder
Modafinil and its R-enantiomer armodafinil are wakefulness-promoting agents approved for narcolepsy, obstructive sleep apnea related sleepiness, and shift work disorder. Their primary mechanism is dopamine transporter inhibition, with downstream effects on orexin and histamine that keep the brain alert. Typical dosing is 100 to 200 mg of modafinil or 150 to 250 mg of armodafinil in the morning, with half-lives of roughly 12 to 15 hours.
For a founder in launch week, the relevant effects from research on healthy adults are:
- Sustained attention holds up longer, particularly when sleep has been short.
- Subjective fatigue drops, which makes the fourteenth hour feel like the eighth.
- Task motivation rises. People on modafinil report enjoying effortful work more and being more willing to persist.
- Some executive function measures improve modestly, such as planning and impulse control, mostly in the sleep deprived.
What it does not do is expand working memory in any meaningful way, improve creative or divergent thinking, or restore the judgment that sleep loss has removed. It reduces the feeling of being overloaded without reducing the load.
The Founder-Specific Risks
Founders face a version of the smart drug risk profile that is sharper than the general one.
Overconfidence in a high-stakes window. Studies on modafinil in healthy volunteers have noted that it increases motivation and subjective performance more than objective accuracy. In a launch, the decisions with the largest consequences, pricing, positioning, whom to hire, are exactly the ones where feeling sure and being right come apart.
Narrowed focus when breadth is needed. A eugeroic is excellent at holding attention on one task. Launch weeks require constant re-prioritization across many. Some founders describe finishing a beautiful four-hour deep-work session on the wrong thing while the important thing burned.
Sleep debt disguised as capacity. Because the drug hides tiredness, a founder can run four or five short nights, feel functional, and then hit a wall on the day the real crisis arrives.
Emotional flatness with a team. Some users report reduced warmth and patience on dosing days. A team under launch pressure notices, and morale is a launch resource too.
The escalation loop. Tolerance to the subjective effect builds with daily use. Founders escalate the dose, add caffeine, add a second nootropic, and arrive at demo day wired, dehydrated, and worse than baseline.
A Launch Protocol That Respects the Limits
If you decide, with a doctor’s involvement, that a cognitive enhancer has a place in your launch, structure matters more than substance.
Before launch: reduce the load itself
The highest-leverage moves have nothing to do with pharmacology.
- Close loops in writing. Every open task goes on a single list with an owner. Working memory is freed when the mind trusts the list.
- Pre-decide the routine decisions. Refund policy, discount authority, who approves copy, what constitutes a rollback. Decisions made in advance cost nothing during the crunch.
- Designate a decision buddy. One person, a co-founder or advisor, who reviews every irreversible decision made during launch week. This is the countermeasure to overconfidence.
- Bank sleep. Two weeks of eight-hour nights before the launch is a real, measurable buffer.
During launch: dose for specific days
Rather than daily use, target the two or three days where sustained attention matters most, typically launch day itself and the day of the biggest external event.
- Dose early: 100 mg of modafinil within an hour of waking. Founders often find 100 mg sufficient and 200 mg counterproductive for breadth of attention.
- Halve caffeine on dosing days. The stack raises heart rate and headache risk with little added benefit.
- Set meal and water alarms. Eugeroics suppress appetite and thirst cues, and a dehydrated founder at hour twelve is not a sharp one.
- Protect a hard stop. Because a morning dose is still active in the evening, use a wind-down routine and keep the bedroom dark; if sleep runs short anyway, skip the next day’s dose.
After launch: drug-free review
Reread every significant decision from launch week on a rested, drug-free morning. If the rested version of you disagrees with the enhanced version, you have learned something about how to use the tool next time.
Comparing the Options Founders Actually Consider
| Option | Onset | Duration | Fit for launch week |
| Modafinil, 100 mg | About 1 hour | Most of the day | Best studied; good for specific days |
| Armodafinil, 150 mg | About 1 hour | Slightly longer | Longer tail hurts sleep more |
| Adrafinil, 300 to 600 mg | 1 to 2 hours, variable | Similar, less predictable | Liver-metabolized prodrug; avoid |
| Caffeine, reduced | 20 minutes | 4 to 6 hours | Fine alone; halve when stacking |
| Prescription amphetamines | Fast | Variable | Higher abuse potential; not a launch tool |
Adrafinil deserves the founder-specific warning. It is legal in the US because it was never scheduled, which makes it tempting as a workaround. It converts to modafinil in the liver, historically at 300 to 600 mg doses, with slower and less predictable onset and documented liver enzyme concerns with chronic use. The original manufacturer discontinued it. A launch is not the week to discover that your unregulated capsule was mislabeled.
The Cognitive Load Toolkit Beyond Pharmacology
Because a smart drug addresses only the attention and fatigue dimensions of overload, the rest of the toolkit does the heavy lifting.
Externalize everything. A whiteboard of the launch’s moving parts, updated hourly, does what working memory cannot. The goal is that no critical fact lives only in your head.
Batch communication. Three fixed windows for email and Slack. A founder who checks messages continuously spends launch week in a state of constant context switching, which is expensive regardless of chemistry.
Time-box the crisis response. When something breaks, set a fifteen-minute triage timer. Decide whether it is a rollback, a patch, or a “we will address this Thursday.” Then return to the plan.
Delegate the reversible. Anything that can be undone is someone else’s decision. Reserve your attention for the irreversible.
Schedule the sleep. Put it on the calendar like a meeting with the lead investor. Six hours is the floor below which judgment measurably fails, and a eugeroic does not raise that floor, it just hides it.
A Sample Launch Week
To make this concrete, here is how a founder might combine the pieces.
Monday and Tuesday. No drug. Final pre-decisions, loop-closing, eight hours of sleep. Coffee as normal.
Wednesday, launch day. 100 mg modafinil at 6:30 a.m., one coffee, meal alarms at noon and 5 p.m., decision buddy on call for anything irreversible. Hard stop at 9 p.m. with a wind-down routine.
Thursday. No drug. Deliberately slower day: bug triage, support responses, a walk. If Wednesday’s sleep was short, this is the recovery day, not the day to double down.
Friday, investor and press day. 100 mg at 6:30 a.m. if Thursday’s sleep was decent; skip it otherwise. Same guardrails.
Weekend. Fully drug-free. Rest, exercise, and the drug-free review of every major decision.
Two dosing days out of seven, the drug used where sustained attention matters most, sleep and judgment protected everywhere else.
The Responsible-Use Note
Modafinil and armodafinil are Schedule IV prescription medicines in the United States, and rules on possession and import vary by country. A founder considering a eugeroic should have a physician involved, ideally one who also checks blood pressure and reviews other medications, and should remember that no productivity aid replaces sleep, which is the one launch resource that cannot be borrowed.
FAQ
Will a smart drug help me think more clearly about strategy? It will help you stay awake and focused while you think, which is not the same thing. For open-ended strategic questions, rested divergent thinking tends to outperform enhanced convergent thinking. Use it for execution days, not for the day you set the pricing.
Can I use modafinil every day for the whole launch month? You can, but most founders who do report diminishing subjective benefit, accumulating sleep debt, and more irritability by week three. Two or three targeted days a week is the pattern that holds up.
What about stacking it with nicotine or high-dose caffeine? The combination pushes heart rate and blood pressure further, increases headache and anxiety, and does little for judgment. If you stack anything, it should be water and food.
How do I know if the drug is making me overconfident? You mostly cannot from the inside, which is why the decision buddy and the drug-free review exist. If those two mechanisms keep catching things, that is your answer.
Is there a founder for whom this is a bad idea entirely? Anyone with untreated high blood pressure, a heart rhythm condition, a history of substance problems, or a pattern of using the drug to avoid sleep rather than to protect it. In those cases the honest move is to fix the sleep and the systems, not the chemistry.
Final Thoughts
A launch is a cognitive load problem, and a smart drug solves only the attention and fatigue slice of it. Modafinil can help a founder stay sharp on the two or three days that matter most, provided the dose is low and early, sleep is protected, and a rested person is checking the irreversible decisions. The rest of the load yields to writing things down, deciding in advance, delegating the reversible, and sleeping on purpose. Founders who get the systems right rarely need much chemistry. Founders who get the chemistry right without the systems usually launch tired, certain, and wrong about something important.
For more topic guides and related resources, visit Modavance.
